Using iPS Cells as Optimal Donor Source for Allogeneic Therapies
Time: 11:00 am
day: Day One
Details:
- Optimising differentiation and expansion of iPSCs to reduce product variability
- Incorporating safe and efficient engineering methods to prevent genetic instability and tumourgenicity
- Overcoming manufacturing challenges to decrease the reliance on donors
